Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about severe Vitamin D deficiency and its potential link to hair loss. The user is already using oral finasteride, topical finasteride, and topical minoxidil for aggressive hair loss.

Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.

The user is currently using Minoxidil with melatonin, rosemary, peppermint, azelaic acid, and RU58841 for hair loss and plans to add fluridil and Pyrilutamide. They seek advice on the best Pyrilutamide source, noting Actifolic worked briefly.

The user is considering liposomal minoxidil due to non-response and side effects from other treatments. They are exploring tretinoin with topical minoxidil as an alternative.

Topical spironolactone is discussed as a potential hair loss treatment for those who can't tolerate finasteride, with some users noting varied results and side effects. Alternatives like laser caps are also mentioned.

Platelet-rich plasma (PRP) therapy for hair loss is expensive, painful, and often ineffective, with mixed reviews on its benefits. Alternatives like minoxidil, finasteride, and hair transplants are suggested as more reliable options.

Pyrilutamide's effect on sebum production and scalp inflammation is unclear, with users noting no significant changes. Isotretinoin is mentioned as effective for reducing sebum, while Dutasteride and various shampoos have limited impact on oiliness and seborrheic dermatitis.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

The conversation discusses the use of low-dose oral minoxidil for hair loss and its potential effects on skin aging. Users shared experiences, with some noting side effects like puffy eyelids and dark circles, but no conclusive evidence of significant collagen depletion or increased wrinkles.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

The user has been using topical minoxidil and finasteride for 1.5 years, which has thickened existing hair but left some areas thin. They suspect the treatment may be causing dandruff or seborrheic dermatitis and are seeking advice.

A 21-year-old experiencing significant hair loss despite using dutasteride, oral minoxidil, ketoconazole shampoo, and low-level laser therapy seeks advice. Suggestions include adding microneedling, checking for vitamin deficiencies or thyroid issues, and considering a scalp biopsy for other conditions.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Topical spironolactone is discussed as a potential treatment for androgenic alopecia, with the user seeking feedback on its effectiveness. Minoxidil, finasteride, and other treatments like microneedling and keto shampoo are mentioned as alternatives.

The user aims to achieve a hypertrichosis look and has used topical Minoxidil for 20 years, now trying oral Minoxidil in a low dose. They seek alternatives to Minoxidil to avoid side effects.

New hair growth from minoxidil and finasteride is not reaching full length, possibly due to slow growth cycles. Users discuss dosing strategies for oral minoxidil to improve efficacy and minimize side effects, with advice against consuming topical minoxidil orally.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

Oleic acid and ethanol are being considered for hair regrowth, with some users planning to self-experiment. There is skepticism about their effectiveness, and ongoing use of treatments like finasteride and minoxidil is mentioned.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses hair loss treatments for a woman experiencing androgenetic alopecia and seborrheic dermatitis, with suggestions including low-dose oral minoxidil, dutasteride, and hormone replacement therapy. The user is seeking advice due to intolerance to spironolactone and topical minoxidil, and concerns about low testosterone and DHT levels.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

There have been no new effective hair loss treatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.

Hair loss discussion includes Pyrilutamide, Minoxidil, and Finasteride. One user shares 3 weeks of Pyrilutamide use with no side effects, unsure of product legitimacy.

The user is frustrated with hair loss despite using minoxidil, topical finasteride, and topical dutasteride, and is considering other options like oral treatments, SMP, or hair systems. They feel demoralized and are struggling with self-esteem and social interactions due to their thinning hair.

Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

A user discusses their hair thinning journey, starting minoxidil at 16, switching treatments, and experiencing significant shedding after resuming minoxidil. They are now using minoxidil daily and considering PRP if shedding continues, while also planning lifestyle changes to improve their condition.

A 43-year-old noticed significant hair thinning and is using topical minoxidil, dermarolling, Alpecin, biotin, zinc, copper, vitamin D, and rosemary oil. They plan to see an endocrinologist and have blood tests scheduled to investigate further.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.